Skip to content

Study · Randomized controlled trial · n = 30 · 2017

10 results

High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.

Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P and 4 more

Show all authors

Maffezzoni F, Montini M, Terzolo M, Ghigo E

The Journal of clinical endocrinology and metabolism1 Jul 2017Cited by 51 (Europe PMC)

PMID28419317 (opens in a new tab)DOI10.1210/jc.2017-00142 (opens in a new tab)PepBankPUB-28419317
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In acromegaly patients, adverse events did not differ between high-dose and high-frequency lanreotide arms.

    In plain wordsAdverse events did not differ between high-dose and high-frequency lanreotide.

    Peptide
    Lanreotide
    Outcome
    No significant changeAdverse events between regimens
    Study

    n = 30

    Comparator
    High-dose versus high-frequency lanreotide
    Outcome group
    Adverse events · Whole body
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall, 19 patients (63.3%) experienced adverse events, all being mild to moderate and transient, without differences between the two therapeutic arms.
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In active acromegaly patients, IGF-I normalization did not differ significantly between high-frequency and high-dose lanreotide (P=0.59).

    In plain wordsIGF-I normalization did not differ significantly between high-frequency and high-dose lanreotide.

    Peptide
    Lanreotide
    Outcome
    No significant changeIGF-I normalization between regimens
    Study

    n: not reported in source

    Comparator
    High-dose versus high-frequency lanreotide
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.59
    IGF-I normalization, high-frequency vs high-dose

    Source sentences

    Summary
    Normalization in IGF-I values occurred in 27.6% of patients (P = 0.016 vs baseline), without a significant difference between HF and HD groups (P = 0.59).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  3. 03HumanNon-randomized trialSafety outcome

    In acromegaly patients receiving lanreotide, 19 (63.3%) experienced adverse events, all mild to moderate and transient.

    In plain wordsAdverse events occurred in 19 patients (63.3%) during lanreotide treatment and were mild to moderate and temporary.

    Peptide
    Lanreotide
    Outcome
    Not applicableOverall adverse events
    Study

    n = 30

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Patients with adverse events
    19 patients
    both regimens combined
    Patients with adverse events
    63.3%
    both regimens combined

    Source sentences

    Summary
    Overall, 19 patients (63.3%) experienced adverse events, all being mild to moderate and transient, without differences between the two therapeutic arms.
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  4. 04HumanNon-randomized trialEfficacy outcome

    In active acromegaly patients, IGF-I decreased during high-dose or high-frequency lanreotide treatment (P=0.007).

    In plain wordsIGF-I decreased from baseline during high-dose or high-frequency lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    DecreaseOverall IGF-I decrease
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.007
    IGF-I decrease during 24-week treatment, all patients

    Source sentences

    Summary
    IGF-I decreased significantly (P = 0.007) during the 24-week treatment, with greater decrease in HD (P = 0.03) vs HF group (P = 0.08).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  5. 05HumanNon-randomized trialEfficacy outcome

    In active acromegaly patients, IGF-I decreased with high-dose lanreotide (P=0.03).

    In plain wordsIGF-I decreased from baseline with high-dose lanreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseIGF-I decrease with high-dose regimen
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.03
    IGF-I decrease in high-dose group

    Source sentences

    Summary
    IGF-I decreased significantly (P = 0.007) during the 24-week treatment, with greater decrease in HD (P = 0.03) vs HF group (P = 0.08).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  6. 06HumanNon-randomized trialEfficacy outcome

    In active acromegaly patients, the IGF-I decrease with high-frequency lanreotide did not reach significance (P=0.08).

    In plain wordsIGF-I did not decrease significantly from baseline with high-frequency lanreotide.

    Peptide
    Lanreotide
    Outcome
    No significant changeIGF-I decrease with high-frequency regimen
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.08
    IGF-I decrease in high-frequency group

    Source sentences

    Summary
    IGF-I decreased significantly (P = 0.007) during the 24-week treatment, with greater decrease in HD (P = 0.03) vs HF group (P = 0.08).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  7. 07HumanNon-randomized trialEfficacy outcome

    In active acromegaly patients, IGF-I normalized in 27.6% during lanreotide treatment (P=0.016 versus baseline).

    In plain wordsIGF-I normalization increased compared with baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    IncreaseIGF-I normalization overall
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    IGF-I normalization
    27.6%
    all patients
    P value
    0.016
    IGF-I normalization vs baseline

    Source sentences

    Summary
    Normalization in IGF-I values occurred in 27.6% of patients (P = 0.016 vs baseline), without a significant difference between HF and HD groups (P = 0.59).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  8. 08HumanNon-randomized trialEfficacy outcome

    In active acromegaly patients, serum GH did not significantly change during lanreotide treatment (P=0.22).

    In plain wordsGrowth hormone did not significantly change from baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    No significant changeSerum GH change
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.22
    serum GH change during treatment

    Source sentences

    Summary
    Serum GH values did not change significantly (P = 0.22).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  9. 09HumanObservational studyMechanism

    In lanreotide-treated acromegaly patients, serum IGF-I decrease correlated with serum lanreotide (P=0.04).

    In plain wordsIn lanreotide-treated patients, IGF-I decrease was linked to blood lanreotide levels.

    Peptide
    Lanreotide
    Outcome
    Not applicableIGF-I decrease association with lanreotide concentration
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.04
    correlation of IGF-I decrease with serum lanreotide

    Source sentences

    Summary
    The decrease in serum IGF-I significantly correlated with serum LAN values (P = 0.04), and normalization of IGF-I was predicted by baseline IGF-I values (P = 0.02).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.
  10. 10HumanObservational studyOther

    In lanreotide-treated acromegaly patients, baseline IGF-I predicted IGF-I normalization (P=0.02).

    In plain wordsIn lanreotide-treated patients, baseline IGF-I was linked to later IGF-I normalization.

    Peptide
    Lanreotide
    Outcome
    Not applicableBaseline IGF-I prediction of normalization
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    120 mg every 21 days or 180 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P value
    0.02
    baseline IGF-I as predictor of IGF-I normalization

    Source sentences

    Summary
    The decrease in serum IGF-I significantly correlated with serum LAN values (P = 0.04), and normalization of IGF-I was predicted by baseline IGF-I values (P = 0.02).
    2 context sentences
    Summary · context
    Twenty-four-week prospective, multicenter, randomized, open-label trial.
    Summary · context
    Thirty patients with active acromegaly, partial responders to SRLs, were randomized to HF (120 mg/21 days; 15 patients) or HD (180 mg/28 days; 15 patients) LAN-ATG.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.